Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Lu Li *Department of Intensive Care Unit/Centre for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.ORCID 0009-0005-2917-0497
Yang Zeng *Department of Intensive Care Unit/Centre for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Minfang Tian *Department of Intensive Care Unit/Centre for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Huijun CaoDepartment of Intensive Care Unit/Centre for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Zhilang QiuKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Cellular Immunotherapy Engineering Research Center of Guizhou Province, School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Guo GuoKey Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Cellular Immunotherapy Engineering Research Center of Guizhou Province, School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.
Feng ShenDepartment of Intensive Care Unit/Centre for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.ORCID 0000-0002-0807-8617
Yuping WangDepartment of Intensive Care Unit/Centre for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.ORCID 0000-0003-2635-5670
Jian PengDepartment of Intensive Care Unit/Centre for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.ORCID 0000-0003-3047-1455
Funding
China Postdoctoral Science Foundation 2022MD723770Department of Health of Guizhou Province gzwkj2023-567Guizhou Medical University 21NSFCP39Guizhou Medical University J[2022]023Natural Science Foundation for Young Scientists of Shanxi Province 82002180, 81660347Science and Technology Program of Guizhou Province ZK[2022] Key Program 039
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The antimicrobial peptide Cec4 has therapeutic potential against clinical carbapenem-resistant · full record | OpenQuestion